Angiogenex Inc

AGGX:OTCPK
RT Quote | Exchange | USD
Last | 12/18/20 EST
0.25UNCH (UNCH)
52 week range
0.01 - 0.40

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.25
  • 52 Week High0.40
  • 52 Week High Date08/13/20
  • 52 Week Low0.01
  • 52 Week Low Date05/11/20
  • Market Cap7.60M
  • Shares Out30.39M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta7.67
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.03
  • P/E (TTM)-8.42
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-0.90M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-13.46%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Angiogenex Inc News

There is no recent news for this security.

Latest AGGX News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
AngioGenex, Inc. is engaged in the discovery and development of drugs that target regulators of gene transcription. The Company’s lead clinical candidate, Idantirx/AGX51, lowers the concentration of Id -inhibitor of differentiation proteins in cancer cells. The Id genes and proteins are not normally present in adult tissues unless pathologic conditions such as cancer are present. AngioGenex has developed a diagnostic test to quantitate Id proteins in blood and expects to use...
Michael Aronstein
Chairman
Michael Strage J.D.
Chief Operating Officer
Martin Murray CPA
Chief Financial Officer
Address
425 Madison Ave Ste 902
New York, NY
10017-1110
United States